Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 2 RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED EXPLORATORY EFFICACY STUDY OF SITAXSENTAN SODIUM TO IMPROVE IMPAIRED EXERCISE TOLERANCE IN SUBJECTS WITH DIASTOLIC HEART FAILURE

NCT00303498 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00303498
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00303498 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 2 RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED EXPLORATORY EFFICACY STUDY OF SITAXSENTAN SODIUM TO IMPROVE IMPAIRED EXERCISE TOLERANCE IN SUBJECTS WITH DIASTOLIC HEART FAILURE
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
March 27, 2006
Completion date
May 1, 2008
Enrollment
200 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

diastolic heart failure